Recent Quotes (30 days)

You have no recent quotes
chg | %

Akela Pharma Inc  

(Public, TSE:AKL)   Watch this stock  
Find more results for AKL
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/15.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 0.36
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin 25.40% 53.17%
Operating margin 25.40% 52.57%
EBITD margin - 57.73%
Return on average assets 69.14% 285.62%
Return on average equity - -
Employees 32 -
CDP Score - -


Suite 130, 11501 Domain Drive
AUSTIN, TX 78758
United States - Map
+1-512-5316202 (Phone)
+1-512-3393050 (Fax)


Akela Pharma, Inc. (Akela) is a drug development company. The Company is a pharmaceutical formulation developer as well as clinical and commercial drug manufacturer for drug products through its PharmaForm subsidiary. PharmaForm engaged in the area of pharmaceutical dosage form development, controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid filled capsules. The Company has a pipeline also includes a growth hormone releasing hormone (GHRH), which is being developed for frailty and wasting in chronic renal disease. PharmaForm, is the Company�s wholly owned subsidiary which is engaged in Formulation and process development/optimization, Handling of potent compounds, Analytical testing, Clinical labeling and packaging and Patent litigation support. On August 9, 2011, the Company discontinued the Fentanyl TAIFUN program. PharmaForm, is the Company�s wholly owned subsidiary.